Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.

Chari A, Stewart AK, Russell SD, Moreau P, Herrmann J, Banchs J, Hajek R, Groarke J, Lyon AR, Batty GN, Ro S, Huang M, Iskander KS, Lenihan D.

Open source

DOI: 10.1182/bloodadvances.2017015545
Published: 2018-07-01
Container: Blood Adv
Publisher: Not recorded
Open access: no

Credibility signals

uncertain Score 51/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2017015545,
  title = {Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.},
  author = {Chari A and  Stewart AK and  Russell SD and  Moreau P and  Herrmann J and  Banchs J and  Hajek R and  Groarke J and  Lyon AR and  Batty GN and  Ro S and  Huang M and  Iskander KS and  Lenihan D.},
  year = {2018},
  journal = {Blood Adv},
  doi = {10.1182/bloodadvances.2017015545},
  url = {https://doi.org/10.1182/bloodadvances.2017015545}
}

RIS

TY  - JOUR
TI  - Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.
AU  - Chari A
AU  -  Stewart AK
AU  -  Russell SD
AU  -  Moreau P
AU  -  Herrmann J
AU  -  Banchs J
AU  -  Hajek R
AU  -  Groarke J
AU  -  Lyon AR
AU  -  Batty GN
AU  -  Ro S
AU  -  Huang M
AU  -  Iskander KS
AU  -  Lenihan D.
PY  - 2018
JO  - Blood Adv
DO  - 10.1182/bloodadvances.2017015545
UR  - https://doi.org/10.1182/bloodadvances.2017015545
ER  -

APA

A, C., AK, S., SD, R., P, M., J, H., J, B., R, H., J, G., AR, L., GN, B., S, R., M, H., KS, I., & D., L. (2018). Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.. Blood Adv. https://doi.org/10.1182/bloodadvances.2017015545

Source records

europe-pmc · retrieved 2026-09-27T02:49:26.077Z
doaj · retrieved 2026-09-27T02:49:26.086Z